BOCH
OVID icon

Blue Owl Capital Holdings’s Ovid Therapeutics OVID Stock Holding History

Blue Owl Capital Holdings’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,904,666
Closed -$4.23M – 89
2026
Q1 		$4.23M Buy
+1,904,666
New +$3.41M 1.14% 24
2024
Q2 		– Sell
-864,822
Closed -$2.64M – 51
2024
Q1 		$2.64M Hold
864,822
– – 0.53% 32
2023
Q4 		$2.78M Buy
+864,822
New +$2.96M 0.67% 25

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Blue Owl Capital Holdings's OVID Position: Q2 2026 in Review

Blue Owl Capital Holdings sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 1,904,666 shares — an estimated $4.23M sold.

Blue Owl Capital Holdings first reported a position in OVID in Q4 2023 and held it in 3 quarters. The position peaked at $4.23M in Q1 2026. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Blue Owl Capital Holdings reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Blue Owl Capital Holdings sold 1,904,666 Ovid Therapeutics shares in Q2 2026, an estimated $4.23M.
  • Blue Owl Capital Holdings first reported a position in Ovid Therapeutics in Q4 2023 and held it in 3 quarters.
  • Blue Owl Capital Holdings's Ovid Therapeutics position peaked at $4.23M in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.